DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Many patients could benefit from starting a PrEP medication—why wait for them to ask for it?
What should you look for to help identify those at risk for HIV?
HIV risk factors can be behavioral, biological, or epidemiologic, and may include3
Past or current STIs
Sexual activity in a high-prevalence area or social network
Self-identified HIV risk
Sexual partners of unknown HIV-1 viremic status
Uncover HIV risk by starting a dialogue with patients about
"Have you or your partner(s) ever had an STI?"
Gaps in PrEP use5
“Have you ever been on a PrEP medication before?”
In a real-world study (N=986),* seroconversions among patients who stopped their PrEP medication saw a 7.5-fold increase compared with patients who continued using their PrEP regimen
HIV testing habits6
"Do you tend to get tested for HIV regularly or just when you think you may have been exposed?"
"Is your sexual partner(s) new or long term? Are you and your partner(s) in an open relationship?"
In one survey (n=3652), 68% of HIV transmissions stemmed from the patient’s main partner
When prescribing DESCOVY FOR PrEP®, consider the following3:
DESCOVY FOR PrEP should be prescribed only to individuals who are confirmed to be HIV-1 negative immediately prior to initial use and who do not have signs or symptoms consistent with acute HIV infection
While using DESCOVY FOR PrEP, HIV-1 screening tests should be repeated at least every 3 months and upon diagnosis of any STIs
Individuals must strictly adhere to the dosing schedule because the effectiveness of DESCOVY FOR PrEP is strongly correlated with adherence
Use DESCOVY for HIV-1 PrEP to reduce the risk of HIV as part of a comprehensive prevention strategy to reduce the risk of STIs
Take an active role—be the connection between appropriate patients at risk of HIV and the initiation of a PrEP medication.
*The study followed patients in San Francisco, CA.
PCP=primary care physician; STI=sexually transmitted infection.